Diagnostic criteria for monoclonal B‐cell lymphocytosis

Gerald E. Marti(Center for Biologics Evaluation and Research), Andy C. Rawstron(Leeds General Infirmary), Paolo Ghia(Fondazione Piemontese per la Ricerca sul Cancro Onlus), Peter Hillmen(Leeds General Infirmary), Richard S. Houlston(Institute of Cancer Research), Neil E. Kay(Mayo Clinic in Arizona), Thérèse Aurran Schleinitz(Center for Biologics Evaluation and Research), Neil E. Caporaso(National Cancer Institute)
British Journal of Haematology
June 1, 2005
Cited by 406

Abstract

Very low levels of circulating monoclonal B-cell subpopulations can now be detected in apparently healthy individuals using flow cytometry. We propose the term 'monoclonal B-cell lymphocytosis' (MBL) to describe this finding. The aim of this document is to provide a working definition of MBL for future clinical, epidemiological and laboratory studies. We propose that the detection of a monoclonal B-cell population by light chain restriction is sufficient to define this condition in individuals not meeting the diagnostic criteria for other B-lymphoproliferative disorders. The majority of individuals with MBL will have cells that are indistinguishable from chronic lymphocytic leukaemia (CLL). However, this blood cell clonal expansion of CD5+ or CD5- B-lymphocytes is age-dependent and immunophenotypic heterogeneity is common. Longitudinal studies are required to determine whether MBL is a precursor state to CLL or other B-lymphoproliferative disease in a situation analogous to a monoclonal gammopathy of undetermined significance and myeloma. Future studies of MBL should be directed towards determining its relationship to clinical disease, particularly in individuals from families with a genetic predisposition to developing CLL.


Related Papers

No related papers found

Powered by citation graph analysis